Concord Drugs Pauses Fundraising Plans Amid Strategic Review

Concord Drugs Ltd. has postponed its proposed ₹149.3 crore fundraising plan via preferential shares and warrants, initially slated for approval at its March 17, 2025, board meeting. The company, grappling with a negative PE ratio (-833.33) and a promoter holding dip to 54.39%, will reassess capital-raising strategies. Earlier, the board approved Q3 FY25 results (Dec 2024) and rescheduled meetings to address financial restructuring. The pause follows consecutive delays in capital hikes since September 2024, signaling cautious financial recalibration.

 

Sources: BSE Filings, ICICI Direct, Economic Times